Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation. — George Fountzilas (2011) | RDL Network
Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation.
Article 2011 en
Authors
GF
George Fountzilas
HK
Helen P. Kourea
MB
Mattheos Bobos
Abstract
1 min read
The safety and activity of the combination of bevacizumab with paclitaxel given either weekly or 3-weekly in patients with MBC is confirmed.
Jim Janinis, George P. Stathopoulos, Paul Nikolaidis, Haralabos P. Kalofonos, Anna Kalogera‐Fountzila, E. Samantas, Gerasimos Aravantinos, Athanassios Anagnostopoulos, Christos Tolis, Thomas Makatsoris, S. Rigatos, Dimitrios Bafaloukos, Meletios A Dimopoulos, John Daniilidis, George Fountzilas
George Fountzilas, A. Athanassiades, Vaios Papadimitriou, Meletios A Dimopoulos, D. Bafaloukos, Gerasimos Aravantinos, C. Nicolaides, Haralabos P. Kalofonos, Pavlos Papakostas, Nikolaos I. Xiros, Esma Razi
Dimitrios Bafaloukos, C. Papadimitriou, Helena Linardou, Gerasimos Aravantinos, Pavlos Papakostas, D. Skarlos, P. Kosmidis, George Fountzilas, Helen Gogas, Haralabos P. Kalofonos, Meletios A Dimopoulos
Discussion(0)
No comments yet. Be the first to comment.